Platform Licensing BMI's Immune Refocusing Technology offers a modular platform to alter antigenicity and immunogenicity, presenting licensing or co-development opportunities with large vaccine developers or CROs seeking novel approaches to vaccines against resistant pathogens and cancer targets.

Dual Market Focus The company targets both human and veterinary biologics, enabling cross-market partnerships with animal health firms and human vaccine players to expand portfolio reach and accelerate commercially viable programs.

Development Partnerships As a lean biotech, BMI could accelerate growth through contract development and manufacturing partnerships to advance preclinical to early clinical programs leveraging IRT for immune refocusing and monoclonal antibody generation.

Regional Advantage Located in Maryland near major biotech clusters and government labs, BMI has potential to engage with NIH, private funders, and defense or biodefense programs for grants, contracts, or collaborations on emerging disease targets.

Unique Value BMI's approach to overcome antigenic variation, including immune modulation to improve safety and half-life, positions it to partner with vaccine developers and biopharma firms facing pathogen variability or immune-evasion challenges.